中国全科医学
中國全科醫學
중국전과의학
Chinese General Practice
2015年
27期
3300-3303
,共4页
糖尿病肾病%蛋白尿%舒洛地特%单核细胞趋化蛋白1
糖尿病腎病%蛋白尿%舒洛地特%單覈細胞趨化蛋白1
당뇨병신병%단백뇨%서락지특%단핵세포추화단백1
Diabetic nephropathies%Proteinuria%Sulodexide%Monocyte chemotactic protein-1
目的：探讨舒洛地特对糖尿病肾病患者血、尿单核细胞趋化蛋白1（ MCP-1）的影响。方法选取2012年1月—2013年12月荆州市第一人民医院肾内科住院治疗的糖尿病肾病患者84例，采用随机数字表法分为对照组和观察组，每组各42例。对照组采用常规皮下注射胰岛素控制血糖，观察组在对照组基础上加用舒洛地特注射液600 LSU，静脉滴注，1次/d，疗程2周；然后采用序贯疗法，舒洛地特软胶囊250 LSU，口服，2次/d，疗程10周，总观察时间为12周，测定患者治疗前后血肌酐、尿素氮、空腹血糖（ FBS ）、24 h 尿蛋白定量、凝血功能、血和尿MCP-1水平。结果治疗前，两组患者血肌酐、尿素氮、FBS、24 h尿蛋白定量、凝血酶原时间（ PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）、纤维蛋白原（FIB）、血和尿MCP-1水平比较，差异均无统计学意义（P >0.05）。治疗后，两组患者血肌酐、尿素氮、FBS、PT、APTT、TT、FIB比较，差异均无统计学意义（P>0.05）；治疗后，观察组患者24 h尿蛋白定量、血和尿MCP-1水平较对照组降低（ P<0.05）。结论舒洛地特能降低糖尿病肾病患者的蛋白尿，其机制可能与降低患者血、尿MCP-1水平有关。
目的：探討舒洛地特對糖尿病腎病患者血、尿單覈細胞趨化蛋白1（ MCP-1）的影響。方法選取2012年1月—2013年12月荊州市第一人民醫院腎內科住院治療的糖尿病腎病患者84例，採用隨機數字錶法分為對照組和觀察組，每組各42例。對照組採用常規皮下註射胰島素控製血糖，觀察組在對照組基礎上加用舒洛地特註射液600 LSU，靜脈滴註，1次/d，療程2週；然後採用序貫療法，舒洛地特軟膠囊250 LSU，口服，2次/d，療程10週，總觀察時間為12週，測定患者治療前後血肌酐、尿素氮、空腹血糖（ FBS ）、24 h 尿蛋白定量、凝血功能、血和尿MCP-1水平。結果治療前，兩組患者血肌酐、尿素氮、FBS、24 h尿蛋白定量、凝血酶原時間（ PT）、活化部分凝血活酶時間（APTT）、凝血酶時間（TT）、纖維蛋白原（FIB）、血和尿MCP-1水平比較，差異均無統計學意義（P >0.05）。治療後，兩組患者血肌酐、尿素氮、FBS、PT、APTT、TT、FIB比較，差異均無統計學意義（P>0.05）；治療後，觀察組患者24 h尿蛋白定量、血和尿MCP-1水平較對照組降低（ P<0.05）。結論舒洛地特能降低糖尿病腎病患者的蛋白尿，其機製可能與降低患者血、尿MCP-1水平有關。
목적：탐토서락지특대당뇨병신병환자혈、뇨단핵세포추화단백1（ MCP-1）적영향。방법선취2012년1월—2013년12월형주시제일인민의원신내과주원치료적당뇨병신병환자84례，채용수궤수자표법분위대조조화관찰조，매조각42례。대조조채용상규피하주사이도소공제혈당，관찰조재대조조기출상가용서락지특주사액600 LSU，정맥적주，1차/d，료정2주；연후채용서관요법，서락지특연효낭250 LSU，구복，2차/d，료정10주，총관찰시간위12주，측정환자치료전후혈기항、뇨소담、공복혈당（ FBS ）、24 h 뇨단백정량、응혈공능、혈화뇨MCP-1수평。결과치료전，량조환자혈기항、뇨소담、FBS、24 h뇨단백정량、응혈매원시간（ PT）、활화부분응혈활매시간（APTT）、응혈매시간（TT）、섬유단백원（FIB）、혈화뇨MCP-1수평비교，차이균무통계학의의（P >0.05）。치료후，량조환자혈기항、뇨소담、FBS、PT、APTT、TT、FIB비교，차이균무통계학의의（P>0.05）；치료후，관찰조환자24 h뇨단백정량、혈화뇨MCP-1수평교대조조강저（ P<0.05）。결론서락지특능강저당뇨병신병환자적단백뇨，기궤제가능여강저환자혈、뇨MCP-1수평유관。
Objective To investigate the effect of sulodexide on serum and urine MCP-1 in patients with type 2 diabetic nephropathy. Methods Enrolled 84 patients with type 2 diabetic nephropathy who received hospitalized treatment in the Department of Nephrology Jingzhou First People's Hospital from January 2012 to December 2013. The patients were divided into control group and observation group using random number table method, with each group 42 patients. Both groups were administrated with conventional subcutaneous infection of insulin to control blood glucose;the observation group was also administrated with the injection of 600 LSU sulodexide once per day for two weeks by the means of intravenous drip,and then the group was orally administrated with 250 LSU sulodexide soft capsule twice per day for ten weeks;the observation lasted for all together 12 weeks. The serum creatinine( Scr),urea nitrogen( BUN),fasting blood sugar( FBS),24 h urinary protein, coagulation function,serum and urine MCP-1 level were measured before and after treatment. Results Before treatment,the two groups were not significantly different(P>0. 05)in Scr,BUN,FBS,24 h urinary protein quantitation,PT,APTT,TT, FIB and serum and urine MCP-1 level. After treatment,the two groups were not significantly different(P >0. 05)in Scr, BUN,FBS,PT,APTT,TT and FIB;after treatment,the observation group was lower(P<0. 05)than the control group in 24 h urinary protein quantitation and serum and urine MCP-1 level. Conclusion Sulodexide can reduce urine protein excretion in patients with diabetic nephropathy,the mechanism of which may be related to the reduction of serum and urine MCP-1 secretion.
